Benzydamine
targets TNF via inhibition
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06676748 | Apr → Dec 2025 overdue | pharyngitis | KK Women's and Children's Hospital | Not yet recruiting | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT07199543 | Apr → Jul 2025 | — | Angelini Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03706781 | Nov → Dec 2017 | — | Angelini Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02720783 | Mar → Oct 2016 | — | Angelini Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02713893 | Sep 2015 → Jun 2016 | — | Angelini Pharma | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05338398 | Apr 2022 → Oct 2023 | chemotherapy-induced oral mucositis | E2Bio Life Sciences, LLC | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06843018 | Nov 2024 → Dec 2026 expected | acute pharyngitis, nasopharyngitis | Valenta Pharm JSC | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01637883 | Jan 2011 → Jul 2012 | — | Prince of Songkla University | Unknown | No outcome recorded |
| Phase 3 | NCT00051441 | ? → Feb 2005 | mucositis, radiation-induced disorder | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT07467759 | Jul → Dec 2025 | mucositis | Latakia University | Completed | No outcome recorded |
| Phase 4 | NCT05055726 | Dec 2021 → Sep 2022 | head and neck cancer, mucositis | Angelini Pharma | Completed | No outcome recorded |
| Phase 4 | NCT04941976 | Aug 2020 → Jun 2021 | acute pharyngitis | Angelini Pharma | Completed | No outcome recorded |
| Phase 4 | NCT03574246 | Jan → Dec 2018 | pharyngitis | Ankara University | Completed | No outcome recorded |
| Phase 4 | NCT03745599 | Nov 2017 → Sep 2018 | — | Near East University, Turkey | Completed | No outcome recorded |
| Phase 4 | NCT02608788 | Sep 2014 → Jul 2015 | pharyngitis | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT07565766 | Feb → May 2013 | gingival disorder | University of Zagreb | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07416136 | Apr → Aug 2025 | impacted teeth, multiple | Marmara University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 13 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06862817 Comparator | Nov 2023 → Apr 2024 | mucositis | Minia University | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06354712 Background | Apr 2024 → Mar 2025 overdue | mucositis | Mansoura University | Recruiting | No outcome recorded |
| Phase 2 | NCT05323058 Comparator | Jul 2022 → Nov 2023 | stomatitis | Cairo University | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04685395 Comparator | Dec 2019 → Jun 2021 | mucositis | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT00814359 Comparator | May 2009 → Sep 2010 | head and neck cancer, mucositis | Juravinski Cancer Centre Foundation | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT06879366 Comparator | Jun 2023 → Dec 2024 | head and neck cancer | October 6 University | Completed | No outcome recorded |
| Phase 4 | NCT05343429 Comparator | Apr → Oct 2022 | pharyngitis | Rehman Medical Institute - RMI | Unknown | No outcome recorded |
| Phase 4 | NCT04373421 Comparator | Aug 2018 → Mar 2019 | impacted teeth, multiple | Yuzuncu Yil University | Completed | No outcome recorded |
| Phase 4 | NCT03074968 Comparator | Mar 2017 → Mar 2018 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02178293 Comparator | Sep 1998 → May 1999 | pharyngitis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07082621 Comparator | Jan 2024 → Mar 2025 | mucositis | Hams Hamed Abdelrahman | Completed | No outcome recorded |
| — | NCT04537819 Background | Mar 2019 → Jan 2020 | acute tonsillitis | Ivano-Frankivsk National Medical University | Completed | No outcome recorded |
| — | NCT04167592 Comparator | Aug → Sep 2018 | — | Indonesia University | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Benzydamine | “Kloroben topical spray containing chlorhexidine gluconate and benzydamine hydrochloride is applied to the surgical site immediately after impacted mandibular third molar...” NCT07416136 ↗20“OBJECTIVES: This study aimed to evaluate the preventive and therapeutic effects of rebamipide gargle in comparison with benzydamine in head and neck cancer patients undergoing...” PMID 38824583 ↗ Jun 2024 “"1.5mg/ml Benzydamine hydrochloride"," S.L.®" spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20...” NCT02608788 ↗ “topical anesthetics agents (BBC \[Benzocaine, Benzydamine, and Cetalkonium chloride\] oral spray - oracure gel)” NCT07082621 ↗ “benzydamine + cetylpyridine chloride” NCT06843018 ↗ “Benzydamine hydrochloridy” NCT04537819 ↗ “Benzydamine Mouthwash” NCT06354712 ↗ |
| Known as | Benzidamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02178293 ↗ |
| Known as | Benzydamine HCL | “benzydamine HCl will be dripped on the cuff of the endotracheal tube 5 minutes before induction of general anesthesia” NCT01637883 ↗5“preoperative gargling of Asprine and Benzydamine HCL to study comparative effects on intensity and duration of POST.” NCT05343429 ↗ “In addition to this, Benzydamine HCL is available on the Egyptian market and its price is economical” NCT04685395 ↗ “Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary” NCT02720783 ↗ “Drug: benzydamine HCl” NCT07199543 ↗ “0.15% Benzydamine HCl” NCT00814359 ↗ |
| Known as | Benzydamine Hydrochloride | “This single-center, open-label, randomized clinical trial evaluates the effect of 0.15% benzydamine hydrochloride (Difflam) oral spray on the severity of radiation-induced oral...” NCT07467759 ↗13“"1.5mg/ml Benzydamine hydrochloride"," S.L.®" spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20...” NCT02608788 ↗ “Benzydamine hydrochloride is a widely used drug in dentistry , a non-steroidal anti-inflammatory drug, has shown topical anti-inflammatory, analgesic, anaesthetic and...” NCT04685395 ↗ “3 ml (4.5 mg) of benzydamine hydrochloride will be dripped on the cuff of the endotracheal tube 5 minutes prior to induction of general anesthesia” NCT01637883 ↗ “Chlorhexidine Gluconate 0.12 % Mouthwash + benzydamine hydrochloride” NCT04373421 ↗ “Drug: Benzydamine Hydrochloride 0.15% Oral gel” NCT06862817 ↗ |
| Known as | Difflam | “This single-center, open-label, randomized clinical trial evaluates the effect of 0.15% benzydamine hydrochloride (Difflam) oral spray on the severity of radiation-induced oral...” NCT07467759 ↗ |
| Known as | Difflam Forte | “"3.0mg/ml Benzydamine hydrochloride" , " Difflam Forte ®" spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that...” NCT02608788 ↗ |
| Known as | S.L. | “"1.5mg/ml Benzydamine hydrochloride"," S.L.®" spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20...” NCT02608788 ↗ |
| Known as | Tantum Verde | “Benzydamine group, which received benzydamine 0.045 g, 30 mL oral sprays (Tantum Verde) and placebo capsules.” NCT03745599 ↗ |
| Action | Inhibit | “It has been shown to reduce the synthesis of TNF-α, IL-1β and prostaglandins” NCT06862817 ↗ |
| Modality | Small molecule | “a non-steroidal anti-inflammatory agent (NSAID)” NCT06676748 ↗ |
| Route | Oral | “0.15% oral rinse” NCT00051441 ↗ |
| Target | TNF | “It has been shown to reduce the synthesis of TNF-α, IL-1β and prostaglandins” NCT06862817 ↗ |